After Salix's $10B deal, is Synergy Pharma on the block?

Gastro drug developer Synergy Pharmaceuticals ($SGYP) is considering putting itself up for sale, Bloomberg reports, perhaps emboldened by the high price secured by competitor Salix Pharmaceuticals ($SLXP). Citing people close to the company, Bloomberg says Synergy is talking to its advisers about strategic alternatives, which could include a sale. The report sent Synergy's shares up about 8% on Thursday, as investors hope Salix's $10 billion valuation could portend another big deal in the space. Story